Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) Director of Life Scienced Mike Farber joined Steve Darling from Proactive with news the company has announced they are adding the South African Variant to their upcoming Bio Safety Level 4 lab study, which is analyzing viral clearance efficacy with the Company's Ivermectin technology.
Farber talks about why they thought this was an important step to take considering there is concern about the variant whether the vaccines are rendered less effective against the variant.